NO20055588L - Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2 - Google Patents

Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2

Info

Publication number: NO20055588L
Authority: NO; Norway
Prior art keywords: crth2; diseases; treatment; pyrimidine derivatives; allergic
Prior art date: 2003-04-25

Application number

NO20055588A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055588D0 (no

Inventor

Takashi Yoshino

Takuya Shintani

Klaus Urbahns

Kevin Bacon

Hiromi Sugimoto

Tai-Wei Ly

Yuji Koriyama

Hiroki Sato

Kazuho Tanaka

Yoshihisa Manabe

Masanori Seki

Original Assignee

Actimis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-25

Filing date

2005-11-25

Publication date

2006-01-24

2005-11-25 Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc

2005-11-25 Publication of NO20055588D0 publication Critical patent/NO20055588D0/no

2006-01-24 Publication of NO20055588L publication Critical patent/NO20055588L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20055588A 2003-04-25 2005-11-25 Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2 NO20055588L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03009384A EP1471057B1 (fr)	2003-04-25	2003-04-25	Derivés de l'acid pyrimidinylacétique pour le traitment des maladies associées au CRTH2
PCT/EP2004/003910 WO2004096777A1 (fr)	2003-04-25	2004-04-14	Derives de pyrimidine utiles pour le traitement des maladies mediees par crth2

Publications (2)

Publication Number	Publication Date
NO20055588D0 NO20055588D0 (no)	2005-11-25
NO20055588L true NO20055588L (no)	2006-01-24

Family

ID=32946880

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055588A NO20055588L (no)	2003-04-25	2005-11-25	Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2

Country Status (33)

Country	Link
US (2)	US7812160B2 (fr)
EP (2)	EP1471057B1 (fr)
JP (2)	JP4671955B2 (fr)
KR (1)	KR101110491B1 (fr)
CN (2)	CN1809539B (fr)
AR (1)	AR043885A1 (fr)
AT (2)	ATE316077T1 (fr)
AU (1)	AU2004233966B2 (fr)
BR (1)	BRPI0409733A (fr)
CA (1)	CA2523439C (fr)
CL (1)	CL43596B (fr)
CY (1)	CY1111295T1 (fr)
DE (2)	DE60303238T2 (fr)
DK (2)	DK1471057T3 (fr)
DO (1)	DOP2004000875A (fr)
ES (2)	ES2257616T3 (fr)
GT (1)	GT200400079A (fr)
HK (1)	HK1095320A1 (fr)
HN (1)	HN2004000129A (fr)
IL (1)	IL171566A (fr)
MX (1)	MXPA05011399A (fr)
MY (1)	MY147984A (fr)
NO (1)	NO20055588L (fr)
NZ (1)	NZ543693A (fr)
PE (1)	PE20050143A1 (fr)
PL (1)	PL1633726T3 (fr)
PT (2)	PT1471057E (fr)
RU (1)	RU2361865C2 (fr)
SI (1)	SI1633726T1 (fr)
TW (1)	TWI353980B (fr)
UY (1)	UY28286A1 (fr)
WO (1)	WO2004096777A1 (fr)
ZA (1)	ZA200508722B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0301010D0 (sv)	2003-04-07	2003-04-07	Astrazeneca Ab	Novel compounds
PT1471057E (pt)	2003-04-25	2006-05-31	Actimis Pharmaceuticals Inc	Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SA04250253B1 (ar) *	2003-08-21	2009-11-10	استرازينيكا ايه بي	احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP1703893B1 (fr) *	2003-12-23	2012-04-11	Genentech, Inc.	Nouveaux anticorps anti-il 13 et utilisations associees
MXPA06007674A (es) *	2004-01-31	2006-09-04	Actimis Pharmaceuticals Inc	Derivados del acido imidazo [1,2-c] pirimidinilacetico.
KR100808742B1 (ko)	2004-03-11	2008-02-29	액테리온 파마슈티칼 리미티드	테트라하이드로피리도인돌 유도체
GB0415320D0 (en)	2004-07-08	2004-08-11	Astrazeneca Ab	Novel compounds
GB0418830D0 (en)	2004-08-24	2004-09-22	Astrazeneca Ab	Novel compounds
ATE517085T1 (de)	2004-11-23	2011-08-15	Astrazeneca Ab	Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
US8796280B2 (en)	2005-04-21	2014-08-05	Merck Serono, S.A.	2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors
NZ562772A (en)	2005-05-24	2010-01-29	Serono Lab	Tricyclic spiro derivatives as CRTH2 modulators
PE20110118A1 (es) *	2005-10-04	2011-03-08	Aventis Pharma Inc	Compuestos de pirimidina amida como inhibidores de pgds
WO2007039736A1 (fr) *	2005-10-06	2007-04-12	Astrazeneca Ab	Nouveaux composes
TW200745003A (en)	2005-10-06	2007-12-16	Astrazeneca Ab	Novel compounds
WO2007062677A1 (fr) *	2005-11-30	2007-06-07	7Tm Pharma A/S	Acides thiazolyl et pyrimidinyl-acetiques et leurs utilisations comme ligands du recepteur crth2
BRPI0712301A2 (pt) *	2006-06-09	2012-01-17	Icos Corp	composto, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
WO2008104869A1 (fr) *	2007-02-26	2008-09-04	Pfizer Products Inc.	Composés hétérocycliques utiles dans le traitement de maladies et de conditions
RU2468013C2 (ru)	2007-06-21	2012-11-27	Актимис Фармасьютикалз, Инк.	Аминовые соли антагониста crth2
CA2690172A1 (fr) *	2007-06-21	2008-12-24	Actimis Pharmaceuticals, Inc.	Particules d'antagoniste de crth2
UA100983C2 (ru)	2007-07-05	2013-02-25	Астразенека Аб	Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
NZ584352A (en) *	2007-09-25	2012-03-30	Actimis Pharmaceuticals Inc	Alkylthio pyrimidines as CRTH2 antagonists
CN101874024A (zh) *	2007-09-25	2010-10-27	艾克提麦斯医药品有限公司	作为crth2拮抗剂的2-s-苄基取代的嘧啶
US8168678B2 (en)	2008-02-01	2012-05-01	Panmira Pharmaceuticals, Inc.	N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en)	2008-02-14	2012-08-14	Panmira Pharmaceuticals, Llc	Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
JP2011513242A (ja)	2008-02-25	2011-04-28	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en)	2008-04-02	2013-04-23	Panmira Pharmaceuticals, Llc	Aminoalkylphenyl antagonists of prostaglandin D2 receptors
MX2010014172A (es)	2008-07-03	2011-02-22	Amira Pharmaceuticals Inc	Antagonistas de receptores de prostaglandina d2.
CA2735722A1 (fr) *	2008-09-02	2010-03-11	Actimis Pharmaceuticals, Inc.	Derives d'acide pyrimidin-5-ylacetique enrichis en isotopes en tant qu'antagonistes de crth2
GB2463788B (en)	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en)	2008-10-01	2013-02-19	Panmira Pharmaceuticals, Llc	Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en)	2008-10-08	2013-09-03	Panmira Pharmaceuticals, Llc	Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en)	2008-11-17	2013-02-26	Panmira Pharmaceuticals, Llc	Heterocyclic antagonists of prostaglandin D2 receptors
RU2011130793A (ru) *	2008-12-25	2013-01-27	Тайсо Фармасьютикал, Ко., Лтд.	Изохинолиновое производное
US20120129820A1 (en)	2009-02-09	2012-05-24	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AU2010212970A1 (en)	2009-02-12	2011-08-18	Merck Serono S.A.	Phenoxy acetic acid derivatives
WO2010094643A1 (fr) *	2009-02-17	2010-08-26	Glaxo Group Limited	Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
US8785393B2 (en)	2009-07-31	2014-07-22	Panmira Pharmaceuticals, Llc	Ophthalmic pharmaceutical compositions of DP2 receptor antagonists
KR20120047273A (ko)	2009-08-05	2012-05-11	판미라 파마슈티칼스, 엘엘씨	Ｄｐ2 길항제 및 이의 용도
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
EA201200765A1 (ru) *	2009-11-24	2013-02-28	Бёрингер Ингельхайм Интернациональ Гмбх	Способ получения полиморфной модификации холиновой соли производного пиримидин-5-илуксусной кислоты
CA2782085A1 (fr)	2010-01-06	2011-07-14	Panmira Pharmaceuticals, Llc	Antagoniste du dp2 et ses utilisations
DK2528901T3 (en)	2010-01-27	2015-08-17	Boehringer Ingelheim Int	Pyrazole compounds as CRTH2 antagonists.
MX2012014667A (es)	2010-06-23	2013-02-15	Taisho Pharma Co Ltd	Derivado de isoquinolina.
JP5800898B2 (ja)	2010-07-05	2015-10-28	アクテリオンファーマシューティカルズリミテッドＡｃｔｅｌｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	１−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
JP2013535456A (ja)	2010-07-28	2013-09-12	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	呼吸器系及び炎症性疾患の治療用医薬組成物
EP2598145A1 (fr)	2010-07-28	2013-06-05	Boehringer Ingelheim International GmbH	Composition pharmaceutique pour le traitement de maladies respiratoires et inflammatoires
RU2560414C2 (ru)	2010-10-20	2015-08-20	Вэлспар Сорсинг, Инк.	Система покрытия на водной основе с улучшенной адгезией к подложкам с покрытием и подложкам без покрытия, в том числе к коррозийно-стойкой нержавеющей стали
KR20140003438A (ko)	2010-11-15	2014-01-09	카톨리에케 유니버시테이트 루벤	항바이러스성 축합 헤테로사이클릭 화합물
EP2457900A1 (fr)	2010-11-25	2012-05-30	Almirall, S.A.	Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
TWI527809B (zh)	2011-01-24	2016-04-01	百靈佳殷格翰國際股份有限公司	作為ｃｒｔｈ２拮抗劑之吡唑化合物
WO2012130633A1 (fr)	2011-03-25	2012-10-04	Boehringer Ingelheim International Gmbh	Composés pyrazoles comme antagonistes du crth2
US8859770B2 (en)	2011-05-16	2014-10-14	Boehringer Ingelheim International Gmbh	Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid
KR20140113667A (ko)	2011-12-16	2014-09-24	아토픽스 테라퓨릭스 리미티드	호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
TW201331179A (zh)	2011-12-21	2013-08-01	Actelion Pharmaceuticals Ltd	雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
CA2876808A1 (fr)	2012-07-05	2014-01-09	Actelion Pharmaceuticals Ltd	Derives heterocyclyles 1-phenyl-substitues et leur utilisation en tant que modulateurs du recepteur de la prostaglandine d2
WO2014079806A1 (fr)	2012-11-23	2014-05-30	Boehringer Ingelheim International Gmbh	Composés de pyrimidine pour traiter l'alopécie
TWI695831B (zh)	2014-09-13	2020-06-11	香港商南北兄弟藥業投資有限公司	Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE790679A (fr)	1971-11-03	1973-04-27	Ici Ltd	Derives de l'indole
JPH03112985A (ja) *	1989-09-28	1991-05-14	Morishita Pharmaceut Co Ltd	Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en)	1991-12-04	1992-02-05	Ici Plc	Heterocyclic derivatives
US6326368B1 (en) *	1996-03-27	2001-12-04	Dupont Pharmaceuticals Company	Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
JP2001302667A (ja)	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PL359862A1 (en) *	2000-05-22	2004-09-06	Leo Pharma A/S	Benzophenones as inhibitors of il-1beta and tnf-alpha
US6878522B2 (en) *	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
EP1413306A1 (fr)	2002-10-21	2004-04-28	Warner-Lambert Company LLC	Dérivé de la tétrahydroquinoline en tant qu'antagonistes de CRTH2
MXPA05006701A (es)	2002-12-20	2006-03-30	Amgen Inc	Moduladores de asma y de inflacion alergica.
PT1471057E (pt)	2003-04-25	2006-05-31	Actimis Pharmaceuticals Inc	Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
RU2468013C2 (ru)	2007-06-21	2012-11-27	Актимис Фармасьютикалз, Инк.	Аминовые соли антагониста crth2
CA2690172A1 (fr)	2007-06-21	2008-12-24	Actimis Pharmaceuticals, Inc.	Particules d'antagoniste de crth2

2003
- 2003-04-25 PT PT03009384T patent/PT1471057E/pt unknown
- 2003-04-25 EP EP03009384A patent/EP1471057B1/fr not_active Expired - Lifetime
- 2003-04-25 DE DE60303238T patent/DE60303238T2/de not_active Expired - Lifetime
- 2003-04-25 DK DK03009384T patent/DK1471057T3/da active
- 2003-04-25 ES ES03009384T patent/ES2257616T3/es not_active Expired - Lifetime
- 2003-04-25 AT AT03009384T patent/ATE316077T1/de active
2004
- 2004-04-01 DO DO2004000875A patent/DOP2004000875A/es unknown
- 2004-04-14 PL PL04727274T patent/PL1633726T3/pl unknown
- 2004-04-14 NZ NZ543693A patent/NZ543693A/en not_active IP Right Cessation
- 2004-04-14 ES ES04727274T patent/ES2358424T3/es not_active Expired - Lifetime
- 2004-04-14 SI SI200431585T patent/SI1633726T1/sl unknown
- 2004-04-14 DE DE602004030907T patent/DE602004030907D1/de not_active Expired - Lifetime
- 2004-04-14 WO PCT/EP2004/003910 patent/WO2004096777A1/fr active Application Filing
- 2004-04-14 BR BRPI0409733-5A patent/BRPI0409733A/pt not_active IP Right Cessation
- 2004-04-14 JP JP2006505114A patent/JP4671955B2/ja not_active Expired - Fee Related
- 2004-04-14 EP EP04727274A patent/EP1633726B1/fr not_active Expired - Lifetime
- 2004-04-14 AU AU2004233966A patent/AU2004233966B2/en not_active Ceased
- 2004-04-14 MX MXPA05011399A patent/MXPA05011399A/es active IP Right Grant
- 2004-04-14 CN CN2004800173378A patent/CN1809539B/zh not_active Expired - Fee Related
- 2004-04-14 RU RU2005136655/04A patent/RU2361865C2/ru not_active IP Right Cessation
- 2004-04-14 DK DK04727274.5T patent/DK1633726T3/da active
- 2004-04-14 CA CA2523439A patent/CA2523439C/fr not_active Expired - Fee Related
- 2004-04-14 ZA ZA200508722A patent/ZA200508722B/en unknown
- 2004-04-14 KR KR1020057020304A patent/KR101110491B1/ko not_active IP Right Cessation
- 2004-04-14 US US10/554,668 patent/US7812160B2/en not_active Expired - Fee Related
- 2004-04-14 AT AT04727274T patent/ATE494279T1/de active
- 2004-04-14 CN CN2010101716294A patent/CN101914065A/zh active Pending
- 2004-04-14 PT PT04727274T patent/PT1633726E/pt unknown
- 2004-04-19 AR ARP040101311A patent/AR043885A1/es not_active Application Discontinuation
- 2004-04-21 HN HN2004000129A patent/HN2004000129A/es unknown
- 2004-04-21 GT GT200400079A patent/GT200400079A/es unknown
- 2004-04-22 MY MYPI20041479A patent/MY147984A/en unknown
- 2004-04-23 TW TW093111323A patent/TWI353980B/zh not_active IP Right Cessation
- 2004-04-23 PE PE2004000402A patent/PE20050143A1/es not_active Application Discontinuation
- 2004-04-23 UY UY28286A patent/UY28286A1/es not_active Application Discontinuation
- 2004-04-23 CL CL200400874A patent/CL43596B/es active
2005
- 2005-10-26 IL IL171566A patent/IL171566A/en not_active IP Right Cessation
- 2005-11-25 NO NO20055588A patent/NO20055588L/no not_active Application Discontinuation
2007
- 2007-01-11 HK HK07100401.6A patent/HK1095320A1/xx unknown
2010
- 2010-08-25 US US12/868,663 patent/US7960393B2/en not_active Expired - Fee Related
- 2010-11-08 JP JP2010249273A patent/JP5161290B2/ja not_active Expired - Fee Related
2011
- 2011-02-03 CY CY20111100113T patent/CY1111295T1/el unknown

Also Published As

Publication number	Publication date
HK1095320A1 (en)	2007-05-04
CL43596B (es)	2005-03-18
SI1633726T1 (sl)	2011-04-29
JP2011068657A (ja)	2011-04-07
NZ543693A (en)	2009-05-31
PL1633726T3 (pl)	2011-06-30
AU2004233966A1 (en)	2004-11-11
DE602004030907D1 (de)	2011-02-17
TWI353980B (en)	2011-12-11
NO20055588D0 (no)	2005-11-25
CN1809539A (zh)	2006-07-26
JP5161290B2 (ja)	2013-03-13
JP4671955B2 (ja)	2011-04-20
AR043885A1 (es)	2005-08-17
AU2004233966B2 (en)	2010-11-11
UY28286A1 (es)	2004-11-30
ZA200508722B (en)	2006-12-27
CA2523439C (fr)	2012-06-19
EP1633726B1 (fr)	2011-01-05
RU2005136655A (ru)	2006-06-10
DOP2004000875A (es)	2004-10-31
MY147984A (en)	2013-02-28
KR20060089622A (ko)	2006-08-09
KR101110491B1 (ko)	2012-01-31
DE60303238T2 (de)	2006-09-14
US7812160B2 (en)	2010-10-12
EP1471057A1 (fr)	2004-10-27
TW200505873A (en)	2005-02-16
PE20050143A1 (es)	2005-04-01
IL171566A (en)	2011-03-31
CN101914065A (zh)	2010-12-15
ES2358424T3 (es)	2011-05-10
RU2361865C2 (ru)	2009-07-20
ATE494279T1 (de)	2011-01-15
PT1633726E (pt)	2011-02-22
CN1809539B (zh)	2012-05-09
JP2006524645A (ja)	2006-11-02
WO2004096777A1 (fr)	2004-11-11
GT200400079A (es)	2004-11-30
DK1471057T3 (da)	2006-05-15
CY1111295T1 (el)	2015-08-05
MXPA05011399A (es)	2006-05-31
EP1471057B1 (fr)	2006-01-18
EP1633726A1 (fr)	2006-03-15
CA2523439A1 (fr)	2004-11-11
US7960393B2 (en)	2011-06-14
DK1633726T3 (da)	2011-03-28
PT1471057E (pt)	2006-05-31
US20100322980A1 (en)	2010-12-23
US20070129355A1 (en)	2007-06-07
BRPI0409733A (pt)	2006-05-09
ES2257616T3 (es)	2006-08-01
DE60303238D1 (de)	2006-04-06
HN2004000129A (es)	2009-05-14
ATE316077T1 (de)	2006-02-15

Publication	Publication Date	Title
NO20055588L (no)	2006-01-24	Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2
CY1109274T1 (el)	2014-07-02	Παραγωγα ιμιδαζο[1,2-c] πυριμιδινυλοξικου οξεος
NO20052076L (no)	2005-04-27	Fuserte azol-pyrimidinderivater.
UA88485C2 (en)	2009-10-26	2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists
TW200610757A (en)	2006-04-01	New pyridazin-3(2H)-one derivatives
MXPA05010055A (es)	2005-11-23	Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
MX2008011369A (es)	2008-09-18	Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2.
TNSN08515A1 (en)	2010-04-14	2-phenyl-indoles as prostaglandin d2 receptor antagonists
NO20080125L (no)	2008-01-08	2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
RU2008118491A (ru)	2009-11-20	Первичная кислая фосфатная соль антагониста рецептора простагландина d2
NO20074207L (no)	2007-10-26	Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
UA88472C2 (en)	2009-10-26	Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
AU2012316912A8 (en)	2014-04-10	Novel heterocyclic derivatives and their uses
WO2004010943A3 (fr)	2004-09-16	Benzanilides substitues utilises comme modulateurs du recepteur ccr5
NO20065757L (no)	2006-12-13	Purinderivater
WO2007062318A3 (fr)	2008-01-17	Composes chimiques
NO20073436L (no)	2007-09-05	Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser
TW200635932A (en)	2006-10-16	New pyridothienopyrimidine derivatives
TW200631954A (en)	2006-09-16	New pyridothienopyrimidine derivatives
EP1666473A4 (fr)	2009-06-03	Composes d'acide carboxylique et compositions medicinales contenant ceux-ci en tant qu'ingredient actif
NO983831L (no)	1998-10-20	Nye substituerte N-metyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamider som er anvendbare for behandling av allergiske sykdommer
DE602006016244D1 (de)	2010-09-30	Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
TH82154A (th)	2007-01-04	อนุพันธ์ไพริโดไธอีโนไพริมิดีนชนิดใหม่
TH84550B (th)	2007-05-17	อนุพันธ์ไพริโดไธอีโนไพริมิดีนชนิดใหม่
WO2007046022A3 (fr)	2008-10-23	Inhibiteurs de phosphodiesterase de type-iv

Legal Events

Date	Code	Title	Description
2014-03-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application